Esperion CFO sells 6,424 shares for tax obligations

Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported an open-market sale of 6,424 shares of common stock at $2.705 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported an open-market sale of 6,424 shares of common stock at $2.705 per share. According to the footnote, the shares were sold to satisfy tax obligations on vested restricted stock units. After this tax-related sale, he directly holds 713,602 shares.

Insider Trade Summary

Net Seller: 6,424 shares

Net Sell 1 txn

Insider Halladay Benjamin

Role Chief Financial Officer

Sold 6,424 shs ($17K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,424	$2.705	$17K

Holdings After Transaction: Common Stock — 713,602 shares (Direct)

Footnotes (1)

F1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Esperion Therapeutics (ESPR) report for Benjamin Halladay?

Esperion Therapeutics reported that CFO Benjamin Halladay sold 6,424 shares of common stock. The transaction was an open-market sale at $2.705 per share, disclosed in a Form 4 insider filing with the SEC for March 17, 2026.

Why did Esperion Therapeutics (ESPR) CFO Benjamin Halladay sell 6,424 shares?

The 6,424 shares sold by CFO Benjamin Halladay were to satisfy tax obligations on vested restricted stock units. A footnote explains the sale was tax-related, indicating it was tied to compensation vesting rather than a discretionary reduction of his equity stake.

How many Esperion Therapeutics (ESPR) shares does the CFO hold after the reported sale?

Following the reported sale, CFO Benjamin Halladay directly holds 713,602 shares of Esperion Therapeutics common stock. This figure comes from the Form 4’s post-transaction ownership line, providing investors with updated visibility into his remaining equity position in the company.

Was the Esperion Therapeutics (ESPR) insider trade a buy or a sell?

The insider trade reported for Esperion Therapeutics CFO Benjamin Halladay was a sale. It is coded as an open-market sale of 6,424 common shares at $2.705 per share, executed on March 17, 2026 and disclosed as a net-sell transaction.

Does the Esperion Therapeutics (ESPR) filing mention options or other derivatives for the CFO?

The filing’s derivative summary is empty, indicating no derivative transactions such as option exercises or warrant conversions were reported in this Form 4. The only activity disclosed is the sale of 6,424 common shares related to tax obligations on vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 04:12 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Halladay Benjamin

(Last)

(First)

(Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR

MICHIGAN

48108

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/17/2026		S		6,424⁽¹⁾	D	$2.705	713,602	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR